Few studies have compared head to head the 2nd generation drug eluting stents. This study randomized 1:1 3671 patients to receive a biolimus eluting stent with biodegradable polymer (1880 patients) versus zotarolimus-eluting stent with biocompatible polymer (1791 patients). No significant differences were observed between the two groups in terms of clinical or angiographic features. Approximately...
Ashok Seth 2012-08-10
Juan F. Granada 2012-08-09
Alexandre Abizaid 2012-08-08
Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press. In recent years there have been new drug-eluting...
Original title: Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. Reference: Wijns W EuroIntervention 2015 Apr 22;10(12):1383-90. Multicenter, randomized study, which enrolled in 26 centers, a total of 184 patients 2:1 (bioabsorbable polymer-coated sirolimus-eluting stent, (SES) [n = 123] versus zotarolimus-eluting stent (ZES) [n = 61]). All patients were evaluated with quantitative...
Original title: Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization Results From the EXPERT CTO (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions) Multicenter Trial. Reference: David E. Kandzari et al. J Am Coll Cardiol Intv. 2015, on line before print. The aim of this study was to evaluate...
Original title: Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease. Reference: Sripal Bangalore, M.D. et al. N Engl J Med. 2015 Mar 26;372(13):1213-22. Coronary artery bypass grafting (CABG) have had better outcomes than percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease. However, this information comes from studies that do not include new generation stents....
Original title: Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Reference: Marco Valgimigli et al. J Am Coll Cardiol. 2015;65(8):805-815. The use of drug eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been studied prospectively. Data on patients at high risk of bleeding and low restenosis are limited. This study compared...